Clareo Health | A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patient, \>/= 18 years of age
Histologically confirmed, unresectable Stage IIIB or IV non-small cell lung cancer (NSCLC)
No prior treatment for unresectable Stage IIIB or IV NSCLC
Measurable radiographic evidence of disease according to RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You may not be if
Prior exposure to agents targeting either the Hepatocyte Growth Factor (HGF) or MET pathway
Exposure to an investigational or marketed agent that can act by EGFR inhibition
Pleural effusion, pericardial fluid, or ascites requiring drainage every other week or more frequently
Brain metastasis or spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated central nervous system (CNS) metastases or spinal cord compression without evidence of clinically stable disease for \>/=4 days. Note: Patients with treated CNS metastases who are asymptomatic and on a stable dose of corticosteroids for \>/= 14 days prior to randomization are eligible.
History of another malignancy in the previous 5 years, unless cured by surgery alone and continuously disease-free
Radiographically evident interstitial lung disease , concurrent infection, or a history of any of these conditions
Inadequate hematologic, biochemical, and organ function
Pregnant or lactating women
Life expectancy of \< 12 weeks
Receipt of an investigational drug within 28 days prior to initiation of study treatment
